Osaic Holdings
RXRX icon

Osaic Holdings’s Recursion Pharmaceuticals RXRX Stock Holding History

Osaic Holdings’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Sell
49,632
-6,694
-12% -$22.3K ﹤0.01% 4504
2026
Q1 		$173K Sell
56,326
-60,640
-52% -$234K ﹤0.01% 4260
2025
Q4 		$478K Sell
116,966
-136,578
-54% -$676K ﹤0.01% 3377
2025
Q3 		$1.19M Buy
253,544
+4,947
+2% +$26K ﹤0.01% 2637
2025
Q2 		$1.26M Sell
248,597
-14,111
-5% -$69.3K ﹤0.01% 2316
2025
Q1 		$1.39M Buy
262,708
+20,518
+8% +$150K ﹤0.01% 1954
2024
Q4 		$1.64M Sell
242,190
-39,277
-14% -$264K ﹤0.01% 1816
2024
Q3 		$1.85M Buy
281,467
+61,519
+28% +$441K ﹤0.01% 1750
2024
Q2 		$1.65M Buy
219,948
+122,416
+126% +$1.07M ﹤0.01% 1772
2024
Q1 		$972K Buy
97,532
+37,426
+62% +$417K ﹤0.01% 2352
2023
Q4 		$593K Buy
60,106
+53,014
+748% +$378K ﹤0.01% 3011
2023
Q3 		$54.2K Buy
7,092
+3,889
+121% +$38.8K ﹤0.01% 4948
2023
Q2 		$23.9K Buy
3,203
+129
+4% +$903 ﹤0.01% 5448
2023
Q1 		$20.5K Sell
3,074
-910
-23% -$7.22K ﹤0.01% 5559
2022
Q4 		$30K Buy
3,984
+599
+18% +$5.87K ﹤0.01% 5293
2022
Q3 		$36K Buy
3,385
+645
+24% +$6.53K ﹤0.01% 5155
2022
Q2 		$22K Sell
2,740
-1,068
-28% -$7.15K ﹤0.01% 5554
2022
Q1 		$27K Buy
3,808
+633
+20% +$6.73K ﹤0.01% 5497
2021
Q4 		$54K Buy
3,175
+780
+33% +$14.7K ﹤0.01% 5089
2021
Q3 		$54K Buy
2,395
+505
+27% +$14.3K ﹤0.01% 5045
2021
Q2 		$69K Buy
+1,890
New +$55.9K ﹤0.01% 4798

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings's RXRX Position: Q2 2026 in Review

Osaic Holdings reduced its Recursion Pharmaceuticals (RXRX) stake by 12% in Q2 2026, selling an estimated $22.3K and leaving 49,632 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #4504.

Osaic Holdings first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.85M in Q3 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Osaic Holdings held 49,632 shares of Recursion Pharmaceuticals worth $182K as of Q2 2026.
  • Osaic Holdings sold 6,694 Recursion Pharmaceuticals shares in Q2 2026, an estimated $22.3K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #4504 holding.
  • Osaic Holdings first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Osaic Holdings's Recursion Pharmaceuticals position peaked at $1.85M in Q3 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.